About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
All
2024
2023
2022
2021
2020
29
Apr
2020
16:30 E.S.T.
Cellectis to Hold First Quarter 2020 Earnings Call on Thursday, May 7, 2020 at 7:30 AM EDT
Read more
13
Apr
2020
16:30 E.S.T.
Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer
Read more
10
Mar
2020
16:30 E.S.T.
US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis
Read more
04
Mar
2020
16:30 E.S.T.
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results
Read more
04
Mar
2020
16:05 E.S.T.
Cellectis and Servier Execute the Amendment Confirming the Expansion of their Collaboration on UCART19 Products
Read more
25
Feb
2020
16:30 E.S.T.
Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST
Read more
18
Feb
2020
16:30 E.S.T.
Cellectis and Servier Expand Collaboration on UCART19 Products
Read more
15
Jan
2020
16:30 E.S.T.
First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia
Read more
12
Jan
2020
16:00 E.S.T.
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
Read more
06
Jan
2020
16:30 E.S.T.
An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery
Read more
Prev
1
2
3